Once-Weekly Semaglutide in Adolescents with Obesity

This double blind, randomized, placebo controlled trial evaluated the efficacy and safety of once weekly subcutaneous semaglutide (2.4 mg) in adolescents (12 to <18 years) with obesity (BMI ≥95th percentile) or overweight (BMI ≥85th percentile with weight related conditions). Participants received semaglutide or placebo plus lifestyle intervention for 68 weeks. The primary endpoint was the percentage change in BMI from baseline to week 68. Results showed a mean BMI reduction of 16.1% with semaglutide versus 0.6% with placebo (estimated difference: -16.7 percentage points; P<0.001). Additionally, 73% of semaglutide participants achieved ≥5% weight loss compared to 18% in the placebo group. Semaglutide also improved cardiometabolic risk factors but was associated with higher gastrointestinal adverse events (62% vs. 42%).

This double blind, randomized, placebo controlled trial evaluated the efficacy and safety of once weekly subcutaneous semaglutide (2.4 mg) in adolescents (12 to <18 years) with obesity (BMI ≥95th percentile) or overweight (BMI ≥85th percentile with weight related conditions). Participants received semaglutide or placebo plus lifestyle intervention for 68 weeks. The primary endpoint was the percentage change in BMI from baseline to week 68. Results showed a mean BMI reduction of 16.1% with semaglutide versus 0.6% with placebo (estimated difference: -16.7 percentage points; P<0.001). Additionally, 73% of semaglutide participants achieved ≥5% weight loss compared to 18% in the placebo group. Semaglutide also improved cardiometabolic risk factors but was associated with higher gastrointestinal adverse events (62% vs. 42%).